Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States, Europe, and internationally.
Excellent balance sheet and slightly overvalued.
Share Price & News
How has Ultragenyx Pharmaceutical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: RARE's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: RARE underperformed the US Biotechs industry which returned 3% over the past year.
Return vs Market: RARE underperformed the US Market which returned 4.1% over the past year.
Price Volatility Vs. Market
How volatile is Ultragenyx Pharmaceutical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StHere's Why We're Not Too Worried About Ultragenyx Pharmaceutical's (NASDAQ:RARE) Cash Burn Situation
1 month ago | Simply Wall StDoes Ultragenyx Pharmaceutical's (NASDAQ:RARE) Share Price Gain of 22% Match Its Business Performance?
2 months ago | Simply Wall StWho Has Been Selling Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares?
Is Ultragenyx Pharmaceutical undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: RARE ($55.74) is trading below our estimate of fair value ($116.54)
Significantly Below Fair Value: RARE is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: RARE is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: RARE is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate RARE's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: RARE is overvalued based on its PB Ratio (4.9x) compared to the US Biotechs industry average (2.9x).
How is Ultragenyx Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 16 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: RARE is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: RARE is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: RARE is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: RARE's revenue (34.3% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: RARE's revenue (34.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: RARE is forecast to be unprofitable in 3 years.
How has Ultragenyx Pharmaceutical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: RARE is currently unprofitable.
Growing Profit Margin: RARE is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: RARE is unprofitable, and losses have increased over the past 5 years at a rate of -24.3% per year.
Accelerating Growth: Unable to compare RARE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: RARE is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (37%).
Return on Equity
High ROE: RARE has a negative Return on Equity (-61.6%), as it is currently unprofitable.
How is Ultragenyx Pharmaceutical's financial position?
Financial Position Analysis
Short Term Liabilities: RARE's short term assets ($851.0M) exceed its short term liabilities ($103.3M).
Long Term Liabilities: RARE's short term assets ($851.0M) exceed its long term liabilities ($378.4M).
Debt to Equity History and Analysis
Debt Level: RARE is debt free.
Reducing Debt: RARE has not had any debt for past 5 years.
Inventory Level: RARE has a low level of unsold assets or inventory.
Debt Coverage by Assets: RARE's debt is not covered by short term assets (assets are -1.1976999512769E+17x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RARE has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if RARE has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Ultragenyx Pharmaceutical's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate RARE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate RARE's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if RARE's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if RARE's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of RARE's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Emil Kakkis (59yo)
Dr. Emil D. Kakkis, MD, Ph.D. has been the Chief Executive Officer and President of Ultragenyx Pharmaceutical Inc. since April 2010. Dr. Kakkis founded Ultragenyx in April 2010. He served as Scientific Adv ...
CEO Compensation Analysis
Compensation vs Market: Emil's total compensation ($USD4.85M) is about average for companies of similar size in the US market ($USD4.93M).
Compensation vs Earnings: Emil's compensation has been consistent with company performance over the past year.
|CFO & Executive VP||7.8yrs||US$2.08m||0.14% $4.5m|
|General Counsel & Executive VP||3.7yrs||US$2.04m||no data|
|Chief Medical Officer & Executive VP||2.1yrs||US$4.85m||0.0021% $69.5k|
|VP, Corporate Controller & Principal Accounting Officer||5.9yrs||no data||0.017% $548.6k|
|Chief Technical Operations Officer & Executive VP||4.8yrs||US$4.24m||0.015% $497.3k|
|Senior Director of Investor Relations & Corporate Communications||0yrs||no data||no data|
|Chief Business Officer & Executive VP||8.3yrs||US$2.33m||0.13% $4.2m|
|Senior Vice President of Regulatory Affairs||0yrs||no data||no data|
|Senior Vice President of Business Development & Alliance Management||1.9yrs||no data||no data|
Experienced Management: RARE's management team is seasoned and experienced (5.3 years average tenure).
|Non-Executive Chairman||4.7yrs||US$563.18k||0.012% $378.5k|
|Independent Director||3.9yrs||US$532.68k||0.012% $378.5k|
|Independent Director||6.1yrs||US$534.18k||0.012% $378.5k|
|Independent Director||6.1yrs||US$550.68k||0.020% $659.0k|
|Independent Director||1.1yrs||no data||no data|
|Independent Director||2.8yrs||US$526.68k||0.0084% $273.3k|
|Independent Director||4.9yrs||US$535.68k||0.012% $378.5k|
|Independent Director||9.1yrs||US$545.68k||0.28% $9.1m|
Experienced Board: RARE's board of directors are considered experienced (4.9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 13.7%.
Ultragenyx Pharmaceutical Inc.'s company bio, employee growth, exchange listings and data sources
- Name: Ultragenyx Pharmaceutical Inc.
- Ticker: RARE
- Exchange: NasdaqGS
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$3.246b
- Shares outstanding: 57.89m
- Website: https://www.ultragenyx.com
Number of Employees
- Ultragenyx Pharmaceutical Inc.
- 60 Leveroni Court
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|RARE||NasdaqGS (Nasdaq Global Select)||Yes||Common Stock||US||USD||Jan 2014|
|UP0||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jan 2014|
|0LIF||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jan 2014|
|RARE *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Jan 2014|
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in the United States, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia; and Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII. The company is also developing small-molecule pipeline comprising UX007, a synthetic triglyceride for the treatment of long chain fatty-acid oxidation disorders, which is a set of rare metabolic diseases that prevents the conversion of fat into energy; gene therapy pipeline consisting of DTX301, an adeno-associated virus 8 gene therapy product candidate for the treatment of patients with ornithine transcarbamylase, as well as DTX401, an AAV8 gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX201, a factor VIII gene therapy program for the treatment of hemophilia A; and GTX-102, an antisense oligonucleotide for the treatment of angelman syndrome. In addition, the company is developing UX701 that is in preclinical development for Wilson disease; UX068, which is in preclinical development for the treatment of creatine transporter deficiency (CTD); and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. was founded in 2010 and is headquartered in Novato, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/02/29 03:29|
|End of Day Share Price||2020/02/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.